Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer

• Published in: Molecular and clinical oncology 2014-01, Vol.2 (1), p.166-170
• Main Authors: VAROL, UMUT, OKTAY, ESIN, YILDIRIM, MUSTAFA, SURMELI, ZEKI GOKHAN, DIRICAN, AHMET, MEYDAN, NEZIH, KARACA, BURCAK, KARABULUT, BULENT, USLU, RUCHAN
• Format: Article
• Language: English
• Subjects: Angiogenesis; Antineoplastic agents; bevacizumab; Cancer metastasis; Cancer therapies; Care and treatment; Chemotherapy; Colorectal cancer; Cytotoxicity; Development and progression; Dosage and administration; Drug dosages; Health aspects; Immunotherapy; Localization; Lymphatic system; Medical prognosis; Medical records; Metastasis; Monoclonal antibodies; Mortality; Oncology; Patients; Statistical analysis; Survival analysis; Targeted cancer therapy; tumor characteristics; Tumors; Turkey; Vascular endothelial growth factor
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2013.212

Colorectal cancer (CRC) is among the most frequently diagnosed cancers and a major cause of cancer-related mortality worldwide. The aim of the present study was to determine whether there was an improvement in the time to disease progression (TTP) in patients with metastatic colorectal cancer (mCRC) treated with first-line bevacizumab plus chemotherapy, according to tumor characteristics and metastatic sites. Tumor characteristics and tumor burden were considered to be predictive markers of the therapeutic efficacy of bevacizumab. The medical records of 705 patients with mCRC were retrospectively reviewed in three oncology centers between January, 2005 and September, 2012. A total of 101 patients completed their first-line bevacizumab-containing treatment. The median TTP was 6.93 months [interquartile range (IQR)=4.20-9.80 months] in patients treated with irinotecan, 5-fluorouracil (5-FU) and bevacizumab vs. 7.42 months (IQR=6.08-10.68 months) in those treated with oxaliplatin, 5-FU and bevacizumab (P=0.589). When we compared patients with pulmonary metastases (median TTP, 9.9000 months) or other metastatic patients without pulmonary metastasis (median TTP, 6.9000 months), we observed a statistically significant difference (P=0.046). However, when the efficacy of bevacizumab was compared in terms of other tumor characteristics (tumor grade, size and lymph node involvement) and metastatic sites, the differences were not significant (P>0.05). We concluded that bevacizumab may be effective in all subgroups of patients with mCRC. Furthermore, bevacizumab with combination chemotherapy may be superior to combination chemotherapy only as the first-line treatment of patients with mCRC and pulmonary metastasis.